Pharmacyclics wins 2nd FDA approval for blood cancer drug Imbruvica

Pharmacyclics Inc. won its second Food and Drug Administration approval Wednesday for the cancer-fighting drug Imbruvica, netting the Sunnyvale company a $60 million milestone payment from a unit of Johnson & Johnson...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.